Debray TPA, Moons KGM, Riley RD (2018) Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: a comparison of new and existing tests
These factors contribute to the development of atherosclerosis, the hardening and narrowing of arteries due to plaque buildup
Tirzepatide is a dual GLP-1/GIP agonist, already FDA- and EMA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound)
GLP-1 receptor agonists represent one of the fastest-growing pharmaceutical classes, with millions of Americans now using these medications for type 2 diabetes and chronic weight management
Researchers on high-dose tirzepatide (10-15 mg) typically begin retatrutide at 4-8 mg rather than the standard 2 mg starting dose, since their GI tract is already adapted to incretin receptor activation
For those with obesity or type 2 diabetes, this number jumps dramatically to over 50% 18